China Clears Two More Homegrown mRNA Vaccines for Clinical Trials

Chinese regulators cleared two domestic vaccine makers to start clinical trials of advanced-technology Covid-19 vaccines, picking up the pace of development to expand the country’s arsenal amid the pandemic’s worst outbreak since 2020.

China's National Medical Products Administration approved clinical trials of a vaccine candidate using the messenger RNA (mRNA) technology developed by Hong Kong-traded vaccine developer CanSino Biologics Inc., the company said Monday.